See more : TT Electronics plc (TTGPF) Income Statement Analysis – Financial Results
Complete financial analysis of Avalon GloboCare Corp. (AVCO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avalon GloboCare Corp., a leading company in the Real Estate – Services industry within the Real Estate sector.
- Avalon Advanced Materials Inc. (AVL.TO) Income Statement Analysis – Financial Results
- Enterprise 4.0 Technology Acquisition Corp. (ENTFU) Income Statement Analysis – Financial Results
- Shandong Hualu-Hengsheng Chemical Co., Ltd. (600426.SS) Income Statement Analysis – Financial Results
- Jeil Pharma Holdings Inc (002620.KS) Income Statement Analysis – Financial Results
- Rasi Electrodes Limited (RASIELEC.BO) Income Statement Analysis – Financial Results
Avalon GloboCare Corp. (AVCO)
About Avalon GloboCare Corp.
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.26M | 1.20M | 1.39M | 1.38M | 1.55M | 1.56M | 1.08M | 616.45K | 0.00 |
| Cost of Revenue | 1.02M | 929.44K | 976.45K | 987.56K | 1.21M | 1.17M | 829.79K | 73.07K | 0.00 |
| Gross Profit | 238.19K | 272.73K | 414.52K | 390.20K | 339.91K | 388.01K | 247.76K | 543.38K | 0.00 |
| Gross Profit Ratio | 18.97% | 22.69% | 29.80% | 28.32% | 21.98% | 24.84% | 22.99% | 88.15% | 0.00% |
| Research & Development | 109.62K | 731.33K | 1.03M | 883.86K | 1.78M | 39.06K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.64M | 5.66M | 8.22M | 11.96M | 16.93M | 7.68M | 2.79M | 459.55K | 31.01K |
| Selling & Marketing | 1.67M | 1.33M | 328.57K | 294.35K | 685.06K | 335.90K | 15.25K | 6.89K | 0.00 |
| SG&A | 7.31M | 6.98M | 8.22M | 11.96M | 16.93M | 8.02M | 2.80M | 466.45K | 31.01K |
| Other Expenses | 8.57M | -120.51K | 4.27K | -4.98K | 3.26K | -11.35K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.99M | 7.72M | 9.25M | 12.84M | 18.71M | 7.96M | 2.78M | 466.45K | 31.01K |
| Cost & Expenses | 17.01M | 8.65M | 10.22M | 13.83M | 19.91M | 9.13M | 3.61M | 539.51K | 31.01K |
| Interest Income | 0.00 | 3.58M | 200.48K | 168.76K | 82.91K | 4.31K | 1.37K | 575.00 | 0.00 |
| Interest Expense | 1.35M | 3.58M | 200.48K | 168.76K | 82.91K | 314.65K | 138.11K | 0.00 | 0.00 |
| Depreciation & Amortization | 329.95K | 466.28K | 438.78K | 378.48K | 506.74K | 522.84K | 181.64K | 26.00 | 175.51K |
| EBITDA | -15.03M | -7.89M | -8.39M | -12.08M | -16.90M | -7.16M | -3.73M | 77.53K | -31.01K |
| EBITDA Ratio | -1,196.61% | -593.84% | -607.58% | -880.57% | -1,192.42% | -454.97% | -218.21% | 12.48% | 0.00% |
| Operating Income | -15.75M | -7.44M | -8.83M | -12.45M | -18.37M | -7.63M | -3.88M | 76.93K | -31.01K |
| Operating Income Ratio | -1,254.59% | -619.12% | -635.08% | -903.93% | -1,187.81% | -488.46% | -359.88% | 12.48% | 0.00% |
| Total Other Income/Expenses | -953.33K | -3.14M | -256.67K | -225.42K | 1.31M | -421.16K | -171.78K | 575.00 | 0.00 |
| Income Before Tax | -16.71M | -11.93M | -9.09M | -12.68M | -18.07M | -8.05M | -4.05M | 77.51K | -31.01K |
| Income Before Tax Ratio | -1,330.51% | -992.44% | -653.54% | -920.29% | -1,168.60% | -515.42% | -375.82% | 12.57% | 0.00% |
| Income Tax Expense | 0.00 | 749.25K | 144.29K | 112.11K | 30.39K | -278.17K | -585.36K | 21.93K | -175.50K |
| Net Income | -16.71M | -12.68M | -9.23M | -12.79M | -18.10M | -7.77M | -3.46M | 55.58K | -31.01K |
| Net Income Ratio | -1,330.51% | -1,054.77% | -663.91% | -928.43% | -1,170.57% | -497.61% | -321.50% | 9.02% | 0.00% |
| EPS | -1.59 | -1.36 | -1.09 | -1.61 | -2.41 | -1.08 | -0.53 | 0.01 | -0.18 |
| EPS Diluted | -1.59 | -1.36 | -1.09 | -1.61 | -2.41 | -1.08 | -0.53 | 0.01 | -0.18 |
| Weighted Avg Shares Out | 10.53M | 9.33M | 8.49M | 7.95M | 7.51M | 7.20M | 6.50M | 5.11M | 175.00K |
| Weighted Avg Shares Out (Dil) | 10.53M | 9.33M | 8.49M | 7.95M | 7.51M | 7.20M | 6.50M | 5.11M | 175.00K |
Avalon GloboCare expands its cellular immuno-oncology program with addition of Chimeric Antigen Receptor-Natural Killer cell therapies
Avalon GloboCare well poised for growth this year; intended SenlangBio acquisition terminated
Avalon GloboCare advances its AI-enhanced protein design technology for cellular therapy development in collaboration with MIT
Avalon GloboCare successfully co-develops novel platform of S-layer coated emulsome technology for next-generation drug delivery and cellular immunotherapy
Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy
Avalon GloboCare announces co-development of in-silico system to expand its ability to design and produce novel cell membrane proteins
Avalon GloboCare's Advanced Filtration Tech Could Help Stop Life-Threatening Cytokine Storm in COVID-19 Patients
Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related Diseases
Avalon GloboCare Aims to Revolutionize Cell Therapy Market with a Faster, Safer CAR-T Treatment
AVALON GLOBOCARE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Avalon GloboCare Corp. - AVCO
Source: https://incomestatements.info
Category: Stock Reports